Press Release
-
(2023-06-30) Aimedbio signs another "ADC Co-development Agreement" with GeneQuantum2023.07.18
-
- Aimedbio has previously signed an agreement with GeneQuantum to co-develop AMB302/GQ1011 on April 2022
- Based on good results, Aimedbio and GeneQuantum decided to sign another ADC co-development agreement to collaborate on a maximum of five ADCs using Aimedbio's antibody development technology and GeneQuantum's linker conjugation technology
Link to full news: https://firstwordpharma.com/story/5758714
